grace capital purchased a new stake in Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 25,917 shares of the specialty pharmaceutical company’s stock, valued at approximately $602,000.

Other hedge funds also recently modified their holdings of the company. Envestnet Asset Management Inc. increased its stake in shares of Valeant Pharmaceuticals by 189.4% in the first quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 3,921 shares during the period. Bedel Financial Consulting Inc. acquired a new stake in shares of Valeant Pharmaceuticals in the second quarter valued at about $116,000. Signaturefd LLC increased its stake in shares of Valeant Pharmaceuticals by 78.6% in the second quarter. Signaturefd LLC now owns 5,248 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 2,309 shares during the period. Assetmark Inc. increased its stake in shares of Valeant Pharmaceuticals by 409.4% in the first quarter. Assetmark Inc. now owns 11,498 shares of the specialty pharmaceutical company’s stock valued at $183,000 after buying an additional 9,241 shares during the period. Finally, Wedbush Securities Inc. acquired a new stake in shares of Valeant Pharmaceuticals in the second quarter valued at about $200,000. 46.95% of the stock is owned by institutional investors.

Shares of Valeant Pharmaceuticals stock opened at $23.40 on Thursday. Valeant Pharmaceuticals has a one year low of $10.94 and a one year high of $27.79. The company has a debt-to-equity ratio of 5.59, a quick ratio of 0.92 and a current ratio of 1.18. The stock has a market cap of $8.16 billion, a P/E ratio of 6.11, a price-to-earnings-growth ratio of 0.35 and a beta of -0.38.

Several brokerages have recently weighed in on VRX. Mizuho reissued a “buy” rating and issued a $31.00 price target on shares of Valeant Pharmaceuticals in a research note on Friday, June 29th. TD Securities cut Valeant Pharmaceuticals from a “buy” rating to a “hold” rating and set a $24.00 price target for the company. in a research note on Friday, June 22nd. Barclays raised Valeant Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $20.00 to $34.00 in a research note on Wednesday, June 6th. HC Wainwright reissued a “hold” rating and issued a $20.00 price target on shares of Valeant Pharmaceuticals in a research note on Wednesday, June 20th. Finally, Deutsche Bank reissued a “buy” rating on shares of Valeant Pharmaceuticals in a research note on Friday, June 29th. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $20.51.

Valeant Pharmaceuticals Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Featured Article: Understanding Relative Strength Index

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.